Identification of Candidate Biomarkers in Peripheral Blood for Cardiac Allograft Rejection based on Bioinformatics

Zhonghua Shen1, Weihua Gong2

  • 1Department of Cardiovascular Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China (mainland).

Insights

Early diagnosis of cardiac allograft rejection (AR) is crucial. This study identifies seven peripheral blood biomarkers, including RPL7 and SCD5, for noninvasive AR monitoring and early detection.

Area of Science:

  • Immunology
  • Genomics
  • Biomarker Discovery

Background:

  • Cardiac allograft rejection (AR) poses significant risks, including graft dysfunction and mortality.
  • Early, noninvasive diagnosis of AR is essential for improved patient outcomes.
  • Peripheral blood biomarkers offer a promising avenue for early AR detection.

Purpose of the Study:

  • To identify candidate biomarkers in peripheral blood for the early, noninvasive diagnosis of cardiac allograft rejection.
  • To analyze gene expression profiles to find differentially expressed genes associated with AR.
  • To investigate the functional pathways of identified biomarkers in the context of AR.

Main Methods:

  • Utilized gene expression profile data (GSE5967) from the Gene Expression Omnibus database.
  • Analyzed peripheral blood samples from cardiac allograft recipients in rejection, post-rejection, and control groups.
  • Applied the limma package for differential gene expression analysis and DAVID for pathway enrichment analysis.

Main Results:

  • Identified 21 up-regulated and 16 down-regulated differentially expressed genes (DEGs) between rejection and control groups.
  • DEGs in rejection were enriched in translation and ribosome-related functions.
  • Identified 3 up-regulated and 14 down-regulated DEGs between post-rejection and control groups, enriched in lipid biosynthesis and membrane functions.

Conclusions:

  • RPL7, RPL11, RPS23, RPS25, SCD5, CSF3R, and FPR1 are predicted as candidate peripheral blood biomarkers for cardiac AR.
  • Up-regulated genes (RPL7, RPS25, RPS23, RPL11) may enhance AR-related cytokine translation.
  • Down-regulated genes (SCD5, CSF3R, FPR1) may impact cell membrane stability and immune cell function, warranting further validation.
Abstract